
Immix Biopharma Inc
NASDAQ:IMMX

Intrinsic Value
The intrinsic value of one
IMMX
stock under the Base Case scenario is
3.147
USD.
Compared to the current market price of 2.095 USD,
Immix Biopharma Inc
is
Undervalued by 33%.
The Intrinsic Value is calculated as the average of DCF and Relative values:

Valuation History
Immix Biopharma Inc
Fundamental Analysis

Revenue & Expenses Breakdown
Immix Biopharma Inc
Balance Sheet Decomposition
Immix Biopharma Inc
Current Assets | 20.2m |
Cash & Short-Term Investments | 17.7m |
Receivables | 2m |
Other Current Assets | 541.4k |
Non-Current Assets | 2.8m |
PP&E | 2.7m |
Other Non-Current Assets | 20.5k |
Free Cash Flow Analysis
Immix Biopharma Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Immix Biopharma Inc
Revenue
|
0
USD
|
Operating Expenses
|
-22.7m
USD
|
Operating Income
|
-22.7m
USD
|
Other Expenses
|
1.1m
USD
|
Net Income
|
-21.6m
USD
|
IMMX Profitability Score
Profitability Due Diligence
Immix Biopharma Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.

Score
Immix Biopharma Inc's profitability score is 37/100. The higher the profitability score, the more profitable the company is.
IMMX Solvency Score
Solvency Due Diligence
Immix Biopharma Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.

Score
Immix Biopharma Inc's solvency score is 53/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
IMMX Price Targets Summary
Immix Biopharma Inc
According to Wall Street analysts, the average 1-year price target for
IMMX
is 7.14 USD
with a low forecast of 7.07 USD and a high forecast of 7.35 USD.
Dividends
Current shareholder yield for IMMX is
.
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one
IMMX
stock under the Base Case scenario is
3.147
USD.
Compared to the current market price of 2.095 USD,
Immix Biopharma Inc
is
Undervalued by 33%.